Journal of Nuclear Medicine Technology February 2026, jnmt.125.271835; DOI: https://doi.org/10.2967/jnmt.125.271835 ...

The growing demand for amyloid and tau PET imaging, driven by new dementia therapies and biomarker-based diagnosis, has increased the need for accessible PET brain imaging in outpatient neurology ...

Neurodegenerative diseases are characterized by progressive neuronal dysfunction, synaptic loss, and decline in cognitive, behavioral, or motor function. Understanding these disorders requires a ...

Journal of Nuclear Medicine Technology February 2026, jnmt.125.271265; DOI: https://doi.org/10.2967/jnmt.125.271265 ...

The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of ...

Journal of Nuclear Medicine Technology February 2026, jnmt.125.271428; DOI: https://doi.org/10.2967/jnmt.125.271428 ...

Neurodegenerative disease profoundly affects structures and pathways responsible for memory, cognition, and higher-order processing. A foundational understanding of neuroanatomy and physiology is ...

Journal of Nuclear Medicine Technology February 2026, jnmt.125.271678; DOI: https://doi.org/10.2967/jnmt.125.271678 Alzheimer disease (AD) is the most common cause of ...

This article is part of a series developed by the Clinical Trials Network of the Society of Nuclear Medicine and Molecular Imaging to offer training and information for molecular imaging technologists ...

PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape ...

In recent years, there has been an influx of new tracers into the field of nuclear medicine and molecular imaging. Most of those that have been Food and Drug Administration–approved for clinical ...